Introduction to the Blood Screening Market
The blood screening
market is an important segment of the healthcare industry. It is used to
diagnose and monitor a wide range of medical conditions, including infectious
diseases, genetic disorders, and other conditions. The market is highly
regulated, with a variety of regulatory bodies and standards that must be
followed. The market is also highly competitive, with a variety of companies
competing for a share of the market. This growth is attributed to the
increasing demand for blood-based diagnostics, the high prevalence of
infectious diseases, and the growing need for personalized medical care.
Global
Blood Screening Market Overview
The global Blood screening market in terms of revenue was estimated to be worth
$2.5 billion in 2021 and is poised to reach $3.8 billion by 2026, growing at a
CAGR of 8.4% from 2021 to 2026.
The global blood
screening market is expected to grow at an impressive rate during the forecast
period. The global blood screening market is driven by the increasing
prevalence of infectious diseases and genetic disorders, rising demand for
effective diagnosis and treatment of diseases, increasing awareness regarding
early diagnosis of diseases, and advancements in technology. The growing number
of collaborations among universities, research institutes, and pharmaceutical
companies is also expected to fuel the growth of the market.
Market
Segmentation
The global blood
screening market is segmented based on technology, application, end user, and
region. By technology, the market is classified into nucleic acid testing,
enzyme-linked immunosorbent assay (ELISA), western blotting (WB), flow
cytometry, immunohematology, and other technologies. By application, the market
is divided into infectious diseases, genetic disorders, and other applications.
By end user, the market is segregated into hospitals.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=267747042
Drivers
of the Blood Screening Market
·
Increasing
prevalence of blood-related diseases: The prevalence of blood-related diseases
such as HIV, hepatitis, and syphilis is increasing globally, which is driving
the need for blood screening.
·
Need
for accurate and reliable results: The demand for accurate and reliable results
from blood screening tests is increasing, due to the need to detect diseases at
an early stage.
·
Rising
awareness of blood safety and donor screening: The rising awareness of the
importance of blood safety and donor screening has led to an increase in the
use of blood screening tests.
·
Growing
demand for blood transfusions: The growing demand for blood transfusions is
driving the need for blood screening tests to ensure the safety of
transfusions.
·
Technological
advancements in blood screening: Technological advancements in the field of
blood screening are enabling the development of more accurate and efficient
tests.
·
Government
initiatives for enhancing blood safety: Governments around the world are taking
initiatives to promote blood safety and donor screening, which is driving the
growth of the blood screening market.
Challenges
Faced by the Blood Screening Market
·
Regulatory
Challenges: Blood screening tests are subject to stringent regulatory
requirements, which can be difficult to meet. This can lead to delays in the
market entry of new products or technologies and can limit the number of
suppliers in the market.
·
Cost
of Testing: Blood screening tests can be expensive, and the cost of testing can
be a barrier to access for some patients.
·
Technological
Limitations: Blood screening tests can be limited by the technology available.
New technologies such as next-generation sequencing are still relatively
expensive and not widely available.
·
Quality
Control: Quality control is an important factor in the accuracy of blood
screening tests. Poor quality control can lead to incorrect results and
potentially dangerous outcomes for patients.
·
Accessibility:
Accessibility to blood screening tests is limited in some areas due to lack of
availability or affordability. This can lead to delays in diagnosis and
treatment.
Regional
Blood Screening Market Analysis
The global blood screening market is
segmented into five major regions: North America, Europe, the Asia Pacific,
Latin America, and the Middle East and Africa. In 2020, North America accounted
for the largest share of the global market. The growth of the North American
market can be attributed to the increasing healthcare spending, the increasing
prevalence of chronic disorders, and the highly developed healthcare systems in
the US and Canada.
Major
Players in the Blood Screening Market
Prominent players operating in this
market are F. Hoffmann-La Roche Ltd. (Switzerland), Grifols (Spain), Abbott
Laboratories, Inc. (US), bioMérieux (France), Bio-Rad Laboratories, Inc. (US)
among others.
Recent
Developments and Trends in the Blood Screening Market
- In May 2021, Beckmann Coulter (US) launched SARS-CoV-2 IgG.
- In September 2021, Roche Diagnostics (Switzerland) acquired
TIB Molbiol Group (Germany). This acquisition will enhance Roche’s broad
portfolio of molecular diagnostics solutions with a wide range of assays
for infectious diseases, such as identifying SARS-CoV-2 variants.
- In February 2020, BD (US) acquired NAT Diagnostics (US), this
acquisition strengthened an early-stage company developing a molecular
diagnostic platform for POC testing.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=267747042
Conclusion:
The Blood Screening
Market is expected to witness significant growth in the coming years due to the
increasing prevalence of infectious diseases, technological advancements, and
the growing demand for blood tests. The market is driven by rising awareness about
the importance of blood screening, increasing demand for safer and more
accurate blood products, and the development of innovative products.
Additionally, the emergence of mobile blood screening technology, government
initiatives, and the growing number of blood testing services and centers are
expected to drive market growth.
No comments:
Post a Comment